Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05650541

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

Led by Analog Device, Inc. · Updated on 2026-01-30

1200

Participants Needed

7

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the Sensinel CPM system against those who are not. This can either be done using institutions' averages, if available, or through a control group.

CONDITIONS

Official Title

Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Heart failure patients of any ejection fraction (HFpEF or HFrEF) with NYHA Class III or IV heart failure
  • Patients with NYHA Class II heart failure plus one or more of the following: chronic kidney disease (eGFR <60 within past 6 months), heart failure hospitalization within 9 months prior to screening, elevated NT-proBNP levels as specified, or chronic obstructive pulmonary disease (COPD)
Not Eligible

You will not qualify if you...

  • Under 18 years of age
  • Severe COPD (GOLD stage III or IV)
  • Limited mobility preventing device application or no caregiver to assist
  • Cognitive impairments limiting device use
  • Skin allergies or sensitivities to silicone-based adhesives
  • Pregnancy
  • Unwillingness to shave chest hair if needed for device application
  • Use of chronic intravenous ionotropic therapy (Milrinone, Dobutamine, Dopamine)
  • Any condition limiting survival to less than one year as assessed by investigator
  • No cellular coverage at patient's home
  • Skin breakdown on the left chest or breast area

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Desert Oasis Healthcare

Palm Springs, California, United States, 92262

Completed

2

Baptist Health South Florida

Miami, Florida, United States, 33173

Actively Recruiting

3

Orlando Health

Orlando, Florida, United States, 32806

Actively Recruiting

4

Baystate Medical Center

Springfield, Massachusetts, United States, 01199

Active, Not Recruiting

5

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68189

Active, Not Recruiting

6

Cone Health

Greensboro, North Carolina, United States, 27401

Completed

7

Prisma Health

Greenville, South Carolina, United States, 29601

Completed

Loading map...

Research Team

E

Emily Wycallis

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here